Payment overview · 2025
General Payments
$1,005.99
28 reported records · 15 companies
Healthcare provider profile · identity verified
Stephen Aulton White, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLARKSVILLE, TN · NPI 1740487305
Verified facts
What the public records show
CMS Open Payments records show Stephen Aulton White, MD received $1,005.99 in general payments during 2025 across 28 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Rexulti, Rybelsus, Synthroid, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 709 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xifaxan by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $231.28 | 23.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $110.71 | 11.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $109.25 | 10.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.32 | 8.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.61 | 7.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.52 | 6.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.70 | 6.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.21 | 5.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.74 | 4.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.00 | 4.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.64 | 3.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.70 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.09 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.90 | 2.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.32 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,005.99 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $231.28 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $110.71 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $109.25 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.32 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.61 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.61 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $65.52 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.74 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.74 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $36.06 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 709 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 120 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 118 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
709 | 86 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1177 | 241 |
| Losartan Potassium | Losartan Potassium | 978 | 216 |
| Levothyroxine Sodium | Levothyroxine Sodium | 931 | 168 |
| Eliquis | Apixaban | 709 | 86 |
| Omeprazole | Omeprazole | 620 | 133 |
| Lisinopril | Lisinopril | 618 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 614 | 127 |
| Furosemide | Furosemide | 595 | 107 |
| Trazodone Hcl | Trazodone Hcl | 579 | 77 |
| Sertraline Hcl | Sertraline Hcl | 548 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 508 | 89 |
| Donepezil Hcl | Donepezil Hcl | 489 | 64 |
| Potassium Chloride | Potassium Chloride | 480 | 60 |
| Metformin Hcl | Metformin Hcl | 472 | 90 |
| Gabapentin | Gabapentin | 447 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 409 | 81 |
| Buspirone Hcl | Buspirone Hcl | 406 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 402 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 378 | 88 |
| Carvedilol | Carvedilol | 376 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 352 | 69 |
| Simvastatin | Simvastatin | 343 | 79 |
| Famotidine | Famotidine | 328 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 327 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 307 | 44 |
| Meloxicam | Meloxicam | 302 | 71 |
| Divalproex Sodium | Divalproex Sodium | 289 | 25 |
| Montelukast Sodium | Montelukast Sodium | 289 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 282 | 57 |
| Alprazolam | Alprazolam | 270 | 50 |
| Mirtazapine | Mirtazapine | 269 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 44 |
| Metformin Hcl Er | Metformin Hcl | 222 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 211 | 25 |
| Levetiracetam | Levetiracetam | 188 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 185 | 34 |
| Allopurinol | Allopurinol | 177 | 30 |
| Januvia | Sitagliptin Phosphate | 175 | 22 |
| Nifedipine Er | Nifedipine | 175 | 27 |
| Baclofen | Baclofen | 143 | 14 |
| Tramadol Hcl | Tramadol Hcl | 142 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | 25 |
| Jardiance | Empagliflozin | 135 | 16 |
| Spironolactone | Spironolactone | 132 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 121 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 120 | 20 |
| Farxiga | Dapagliflozin Propanediol | 120 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 24 |
| Clonidine Hcl | Clonidine Hcl | 118 | 21 |
| Synthroid | Levothyroxine Sodium | 118 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 19 |
| Prednisone | Prednisone | 113 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 53 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 112 | 14 |
| Diazepam | Diazepam | 111 | 18 |
| Memantine Hcl | Memantine Hcl | 104 | 22 |
| Pregabalin | Pregabalin | 103 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 18 |
| Ezetimibe | Ezetimibe | 98 | 25 |
| Alendronate Sodium | Alendronate Sodium | 97 | 17 |
| Atenolol | Atenolol | 96 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 93 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 19 |
| Olanzapine | Olanzapine | 89 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 22 |
| Sucralfate | Sucralfate | 85 | suppressed |
| Glimepiride | Glimepiride | 82 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 82 | 12 |
| Celecoxib | Celecoxib | 81 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 80 | 16 |
| Fenofibrate | Fenofibrate | 78 | 22 |
| Lamotrigine | Lamotrigine | 77 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 76 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | 20 |
| Xarelto | Rivaroxaban | 72 | 12 |
| Bupropion Xl | Bupropion Hcl | 70 | 11 |
| Lorazepam | Lorazepam | 67 | 23 |
| Midodrine Hcl | Midodrine Hcl | 67 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 65 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 64 | suppressed |
| Ondansetron Odt | Ondansetron | 63 | 24 |
| Risperidone | Risperidone | 63 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 13 |
| Lovastatin | Lovastatin | 62 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 13 |
| Trulicity | Dulaglutide | 61 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 12 |
| Finasteride | Finasteride | 58 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 57 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | suppressed |
| Lactulose | Lactulose | 56 | 18 |
| Clomipramine Hcl | Clomipramine Hcl | 55 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 32 |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Fluconazole | Fluconazole | 51 | 33 |
| Methenamine Hippurate | Methenamine Hippurate | 51 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 16 |
| Methadone Hcl | Methadone Hcl | 49 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 49 | suppressed |
| Amantadine | Amantadine Hcl | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | suppressed |
| Colchicine | Colchicine | 47 | 14 |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 26 |
| Prazosin Hcl | Prazosin Hcl | 46 | suppressed |
| Glipizide | Glipizide | 45 | 13 |
| Meclizine Hcl | Meclizine Hcl | 45 | 19 |
| Topiramate | Topiramate | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 34 |
| Diltiazem 24hr Er | Diltiazem Hcl | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 41 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Nystatin | Nystatin | 40 | 22 |
| Ramipril | Ramipril | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Primidone | Primidone | 37 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 37 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 22 |
| Azithromycin | Azithromycin | 35 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Carbamazepine Er | Carbamazepine | 34 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 34 | 23 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 34 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Haloperidol | Haloperidol | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 21 |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 19 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Anastrozole | Anastrozole | 27 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Dulera | Mometasone/Formoterol | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | 11 |
| Lidocaine Hcl | Lidocaine Hcl | 26 | 22 |
| Linzess | Linaclotide | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 18 |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | suppressed |
| Jantoven | Warfarin Sodium | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Austedo | Deutetrabenazine | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | 16 |
| Metronidazole | Metronidazole | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Azathioprine | Azathioprine | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 17 | suppressed |
| Lamotrigine Odt | Lamotrigine | 17 | suppressed |
| Leflunomide | Leflunomide | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Metaxalone | Metaxalone | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Tetrabenazine | Tetrabenazine | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,005.99 · 28 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, INGREZZA, Kerendia, Korlym, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SYNTHROID, The Cologuard Plus Collection Kit, UBRELVY, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error